Abstract | OBJECTIVES: SEARCH STRATEGY: Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories and Roche Products Limited. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Data was to be abstracted independently by each author and differences settled by discussion. MAIN RESULTS: REVIEWER'S CONCLUSIONS: Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported.
|
Authors | C E Clarke, J M Speller |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 2
Pg. CD001515
( 2000)
ISSN: 1469-493X [Electronic] England |
PMID | 10796801
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Antiparkinson Agents
- Levodopa
- Lisuride
|
Topics |
- Antiparkinson Agents
(adverse effects, therapeutic use)
- Dyskinesia, Drug-Induced
(drug therapy, etiology)
- Humans
- Levodopa
(adverse effects)
- Lisuride
(therapeutic use)
- Parkinson Disease
(drug therapy)
|